Desirée Thielke

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Bernard Zinman, Vaishali Bhosekar, Robert S. Busch et al. · The Lancet Diabetes & Endocrinology · 2019 · 367 citations

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Ildiko Lingvay, Andrei‐Mircea Catarig, Juan P. Frías et al. · The Lancet Diabetes & Endocrinology · 2019 · 291 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

Rory J. McCrimmon, Andrei‐Mircea Catarig, Juan P. Frías et al. · Diabetologia · 2020 · 159 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

Emelie Andersson, Sofie Persson, Nino Hallén et al. · Diabetologia · 2020 · 85 citations · Full text

Medicine, Health Sciences, Internal Medicine +15

Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach

Rune Viig Overgaard, Søren Lindberg, Desirée Thielke · Diabetes Obesity and Metabolism · 2018 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16